Clinical Trial

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab combined with sindilizumab and chemotherapy in first-line treatment of advanced or recurrent or metastatic esophageal cancer.
Trial Details
NCT Number NCT06718205
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Esophageal Cancer
Enrollment 112 participants
Start Date 2023-03-08
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-12-05